LEP and breast cancer: Dysregulation of the leptin/leptin receptor has been suggested to participate in the development of a large variety of malignancies, including breast cancer, pancreatic cancer, thyroid cancer, endometrial cancer, and gastrointestinal cancer, predominantly through the JAK/STAT pathway (42, 43).